Replies to post #9390 on GTC Biotherapeutics (fka GTCB)

[silly beaver]

Instead of a reverse split GTCB should be listed on the pink sheets or OTCBB. In fact, this move I believe would save the company money because they wouldn't need to incurr the costs associated with Sarbanes-Oxley. If at a later time when the company is successful and the share price is around $4-5 and they want to go back on the Nasdaq to attract more investment capital they should apply to get listed on Nasdaq again.